Jun Health Secures $￥10 Million in Series A Funding

(VCBeat) July. 28, 2021 -- Jun Health, a company focusing on cancer diagnostics at the single-cell level, recently announced a Series A financing of tens of millions. The company is unique in liquid biopsy and independently develops the global original technology platform to join the new race of early screening and diagnosis of single-cell tumors after winning the first certificate of domestic single-cell clinical diagnosis in 2020.

Yan Zhuohui, founder and CEO of Jun Health, said, "We are very pleased to gain the trust and continuous support of experienced industrial investors, which accelerate the commercialization and promotion of Jun Health's clinical products invented by Chinese scientists. The Series A financing will enable Junhui to build a new "single-cell diagnosis" track, promote the marketing of bladder tumor detection products, and accelerate the cooperation with many clinical experts to carry out more registration of single-cell based products used in tumor detection."

In the Chinese market alone, the non-invasive urinary bladder cancer detection products launched by Jun Health can cover the physical examination and screening of hundreds of millions of high-risk people, the auxiliary diagnosis of tens of millions of hematuria patients, and the recurrence monitoring of nearly one million bladder cancer patients. The market size is huge. In 2021, Jun Health will start to accelerate the application of "Uro Energy™ Noninvasive Test for Bladder Cancer" to hospitals. At present, it has carried out clinical cooperation with dozens of first-class hospitals at grade 3 such as Huashan Hospital of Fudan University, Cancer Hospital of Chinese Academy of Medical Sciences, Fudan University Cancer Hospital, the First Affiliated Hospital of Harbin Medical University and Zhejiang Cancer Hospital, and has been highly recognized by clinical experts.

Yan Zhuohui, founder and CEO of Jun Health, said, "Over the past four years, Jun Health has successfully applied "single-celled multiple omics" in bladder cancer screening and early detection. In the next 2-3 years, our focus is to finish clinical research and registration of early detection products for lung cancer and many kinds of cancer metastasis of cancers, to monitor tumor metastasis of patients. By single-cell sequencing and drug treatment, the cancer patients can be cured in time and avoid deaths due to metastasis."